0 XP 0   0   0  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

Kalvista Pharmaceuticals Inc - Trending symbols

Latest News of Kalvista Pharmaceuticals Inc

DateTitleRead
2025-07-11
13:25
Kalvista stock maintains Buy rating at H.C. Wainwright on favorable Ekterly labelRead
2025-07-09
14:16
KalVista price target raised to $37 from $22 at BofARead
2025-07-07
16:36
Kalvista stock jumps as Stifel reiterates Buy rating on Ekterly approvalRead
2025-07-07
16:06
KalVista Pharmaceuticals rises after FDA nod for EkterlyRead
2025-07-07
15:35
U.S. stocks slip lower on uncertainty over Trump tariffs; Tesla falls hardRead
2025-07-07
14:25
US FDA approves KalVista Pharma's swelling disorder drug, shares riseRead
2025-06-24
21:19
FDA's Makary sought to reject KalVista’s drug: reportRead
2025-06-14
05:55
FDA Delays Decision On KalVista's Sebetralstat NDA For Hereditary AngioedemaRead
2025-06-13
23:03
KalVista said FDA will not meet review date for sebetralstatRead
2025-06-13
22:12
FDA delays decision on KalVista's HAE treatment sebetralstatRead

Notifications

TypeNotificationDate
RSI OverboughtOverbought RSI (Relative Strength Index)2025-07-08



Trends

 2024-01-312024-04-302024-07-312024-10-312025-01-31
Total Other Income Expense Net 4,123-3183,805-333,772-2293,543-4,865-1,322
Net Interest Income 6848291,5131791,692-3351,357-2,805-1,448
Gross Profit -324125-1992-197-10-2071,194987
Income Tax Expense -1,958-1,041-2,999-759-3,758-3,213-6,97120,69913,728
Interest Expense 268-26242207449283732-2,155-1,423
Depreciation and Amortization 3476611,008-333675-185490-1,087-597
EBITDA -18,034-1,299-19,333-3,863-23,196729-22,46725,1882,721
Long-term Assets Other 181192000200-7193-149,212-149,019
Long-term Liabilities 1,1233,9235,0461,4286,474-2506,224-8,406-2,182

Comments

How you think about this?

Leave a comment

Stay informed about Kalvista Pharmaceuticals Inc.

Receive notifications about Kalvista Pharmaceuticals Inc in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.